Epignathus

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:141077D37.0
Who is this for?
Show terms as
15Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Epignathus is an extremely rare congenital teratoma that arises from the oral cavity, most commonly from the hard or soft palate, but occasionally from the pharynx, jaw, or tongue. It is a type of oropharyngeal teratoma composed of tissues derived from all three embryonic germ layers (ectoderm, mesoderm, and endoderm), and may contain differentiated structures such as teeth, bone, cartilage, neural tissue, and skin. Epignathus is typically detected prenatally via ultrasound or at birth, presenting as a mass protruding from the mouth. The tumor is classified under ICD-10 as D37.0, reflecting its uncertain neoplastic behavior. The primary clinical concern with epignathus is airway obstruction, which can be life-threatening at birth. Large tumors may cause feeding difficulties, respiratory distress, and in severe cases neonatal asphyxia if not promptly managed. Prenatal complications may include polyhydramnios (excess amniotic fluid) due to impaired fetal swallowing, and very large masses can cause difficulty during delivery. Some cases are associated with cleft palate or other craniofacial anomalies. Rarely, intracranial extension of the tumor has been reported, which significantly complicates management. Treatment is primarily surgical excision of the mass, ideally performed as soon as the airway is secured. In cases diagnosed prenatally where significant airway compromise is anticipated, an EXIT (Ex Utero Intrapartum Treatment) procedure may be planned to establish the airway during delivery while the infant remains on placental circulation. The majority of epignathus tumors are histologically benign (mature teratomas), and complete surgical resection generally carries a favorable prognosis. However, outcomes depend on tumor size, location, degree of airway obstruction, and the presence of intracranial extension. Malignant transformation is exceedingly rare but has been reported. Long-term follow-up is recommended to monitor for recurrence and to address any residual craniofacial defects.

Also known as:

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Epignathus.

View clinical trials →

No actively recruiting trials found for Epignathus at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Epignathus community →

Specialists

15 foundView all specialists →
VT
Vinit Kumar Thakur
SPRINGFIELD, IL
Specialist
1 Epignathus publication
NK
Noppasin Khwankaew
Specialist
1 Epignathus publication
RS
Rapphon Sawaddisan
Specialist
1 Epignathus publication
CG
Cynthia Minerva Gonzalez-Cantu
Specialist
2 Epignathus publications
PM
Pablo Juan Moreno-Peña
Specialist
2 Epignathus publications
MS
Mayela Guadalupe Salazar-Lara
Specialist
2 Epignathus publications
PG
Pablo Patricio Flores García
Specialist
2 Epignathus publications
FM
Fernando Félix Montes-Tapia
Specialist
2 Epignathus publications
VC
Victor Hugo Cervantes-Kardasch
Specialist
2 Epignathus publications
YC
Yanko Castro-Govea
Specialist
2 Epignathus publications
CB
Christoph Bührer
Specialist
1 Epignathus publication
RL
Rohit Lal
Specialist
1 Epignathus publication
AD
Aylin Önder Dirican
Specialist
1 Epignathus publication
KH
Kathrin Hauptmann
KANSAS CITY, MO
Specialist
1 Epignathus publication
RB
Robert Bindermann
Specialist
1 Epignathus publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Epignathus.

Search all travel grants →NORD Financial Assistance ↗

Community

Open EpignathusForum →

No community posts yet. Be the first to share your experience with Epignathus.

Start the conversation →

Latest news about Epignathus

No recent news articles for Epignathus.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Epignathus

What is Epignathus?

Epignathus is an extremely rare congenital teratoma that arises from the oral cavity, most commonly from the hard or soft palate, but occasionally from the pharynx, jaw, or tongue. It is a type of oropharyngeal teratoma composed of tissues derived from all three embryonic germ layers (ectoderm, mesoderm, and endoderm), and may contain differentiated structures such as teeth, bone, cartilage, neural tissue, and skin. Epignathus is typically detected prenatally via ultrasound or at birth, presenting as a mass protruding from the mouth. The tumor is classified under ICD-10 as D37.0, reflecting it

How is Epignathus inherited?

Epignathus follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Epignathus typically begin?

Typical onset of Epignathus is neonatal. Age of onset can vary across affected individuals.

Which specialists treat Epignathus?

15 specialists and care centers treating Epignathus are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.